miRNA Expression Profiling of the Murine TH-\textit{MYCN} Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs

Marta Terrile\textsuperscript{1,2}, Kenneth Bryan\textsuperscript{1,2}, Lynsey Vaughan\textsuperscript{3}, Albert Hallsworth\textsuperscript{3}, Hannah Webber\textsuperscript{3}, Louis Chesler\textsuperscript{3\#}, Raymond L. Stallings\textsuperscript{1,2*}

\textsuperscript{1}Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland, \textsuperscript{2}Ireland and National Children’s Research Centre, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland, \textsuperscript{3}Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom

Abstract

\textbf{Background:} MicroRNAs are small molecules which regulate gene expression post-transcriptionally and aberrant expression of several miRNAs is associated with neuroblastoma, a childhood cancer arising from precursor cells of the sympathetic nervous system. Amplification of the \textit{MYCN} transcription factor characterizes the most clinically aggressive subtype of this disease, and although alteration of p53 signaling is not commonly found in primary tumors, deregulation of proteins involved in this pathway frequently arise in recurrent disease after pharmacological treatment. \textit{TH-MYC} is a well-characterized transgenic model of \textit{MYCN}-driven neuroblastoma which recapitulates many clinicopathologic features of the human disease. Here, we evaluate the dysregulation of miRNAs in tumors from \textit{TH-MYC} mice that are either wild-type (TH-MYC) or deficient (TH-MYC/p53\textsuperscript{ERTAM}) for the p53 tumor suppressor gene.

\textbf{Principal Findings:} We analyzed the expression of 591 miRNAs in control (adrenal) and neuroblastoma tumor tissues derived from either TH-MYC or TH-MYC/p53\textsuperscript{ERTAM} mice, respectively wild-type or deficient in p53. Comparing miRNA expression in tumor and control samples, we identified 159 differentially expressed miRNAs. Using data previously obtained from human neuroblastoma samples, we performed a comparison of miRNA expression between murine and human tumors to assess the concordance between murine and human expression data. Notably, the miR-17-5p-92 oncogenic polycistronic cluster, which is over-expressed in human \textit{MYCN} amplified tumors, was over-expressed in mouse tumors. Moreover, analyzing miRNAs expression in a mouse model (TH-MYC/p53\textsuperscript{ERTAM}) possessing a transgenic p53 allele that drives the expression of an inactive protein, we identified miR-125b-3p and miR-676 as directly or indirectly regulated by the level of functional p53.

\textbf{Significance:} Our study represents the first miRNA profiling of an important mouse model of neuroblastoma. Similarities and differences in miRNAs expression between human and murine neuroblastoma were identified, providing important insight into the efficacy of this mouse model for assessing miRNA involvement in neuroblastoma and their potential effectiveness as therapeutic targets.

\textbf{Citation:} Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, et al. (2011) miRNA Expression Profiling of the Murine TH-MYC Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs. PLoS ONE 6(12): e28356. doi:10.1371/journal.pone.0028356

\textbf{Editor:} Carlo Gaetano, Istituto Dermopatico dell’Immacolata, Italy

\textbf{Received} September 16, 2011; \textbf{Accepted} November 7, 2011; \textbf{Published} December 2, 2011

\textbf{Copyright:} © 2011 Terrile et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\textbf{Funding:} This work was supported in part by Science Foundation Ireland (07/IN.1/B1776), Children’s Medical and Research Foundation, and The Neuroblastoma Society, grant NES003X. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

\textbf{Competing Interests:} The authors have declared that no competing interests exist.

\# E-mail: rstallings@rcsi.ie

* These authors contributed equally to this work.

Introduction

Neuroblastoma is among the most common of childhood tumors and accounts for 15% of pediatric cancer deaths. The disease is clinically heterogeneous, with behavior ranging from spontaneous regression to rapid progression. Multiple genetic abnormalities have been identified that are predictive of clinical outcome and that play important roles in neuroblastoma pathogenesis [1]. Amplification of the gene encoding the \textit{MYCN} transcription factor is the most potent genetic predictor of poor patient outcome and delineates a distinct genetic subtype of high-risk neuroblastoma [2]. As a transcription factor, \textit{MYCN} directly regulates the expression of a large set of genes and microRNAs (miRNA), whose major functions include regulation of cell cycle progression, proliferation, differentiation and apoptosis. [3–5].

MiRNAs are small molecules (22–24 nucleotides) of RNA which negatively regulate gene expression at a post-transcriptional level. The binding of miRNAs to complementary sites on the 3’ UTRs of protein coding mRNA sequences results in either degradation of the mRNA or translational inhibition [6]. MiRNAs are involved with the regulation of many normal physiological processes and their dysregulation contributes to the pathogenesis of virtually all forms of cancer [7,8], including neuroblastoma [9–11]. A number of miRNA expression profiling studies have shown that miRNA
expression is deregulated in MYCN amplified (MNA) tumors relative to MYCN non-amplified tumors (non-MNA), and that miRNA expression signatures are independently predictive of patient survival [12-17]. Moreover, functional studies have also demonstrated that specific miRNAs promote neuroblastoma cell proliferation in vitro and in vivo assays [18,19], or alternatively, act to suppress tumorigenesis by stimulating/reactivating apoptosis [20,21] and differentiation [22] or by inhibiting cell invasion [23].

TH-MYCN is a murine transgenic model of neuroblastoma that is increasingly used for a variety of molecular and pre-clinical studies [24]. Tumorigenesis is driven by neural crest-specific expression of a human MYCN transgene. These animals develop aggressive tumors that replicate major features of MNA high-risk disease [24-26]. The oncogenic action of MYC proteins is strongly enhanced in a variety of cancers by loss of p53, a functional interaction that has been replicated by the introduction of MYC-driven transgenic models in a p53-deficient background [27]. Alterations in p53 signaling are rarely observed in neuroblastoma driven transgenic models in a p53-deficient background [28]. Indeed, murine neuroblastoma is correlating with therapeutic resistance and reinforcing the notion that strong selective pressure for p53 inactivation exists in MYCN-driven neuroblastoma [28,29]. Indeed, murine neuroblastoma is strongly enhanced by placing TH-MYCN into a p53 insufficient background, and this is concomitant with reduced apoptosis and chemotherapy resistance [25]. The interplay between MYCN and p53, however, is complex. MYCN directly up-regulates p53 transcriptional expression [30], but also inhibits p53 through the direct up-regulation of MDM2, which encodes for a ubiquitin ligase that targets tumor protein p53 for proteasomal degradation [31]. Taken together these observations highlight the utility of these preclinical models for studies of MYCN-p53 control mechanisms [25].

Since miRNA expression levels are associated with clinical tumor grade, metastasis and overall survival in neuroblastoma, miRNAs are potential targets for therapeutic treatment. The availability of transgenic models with altered expression of individual oncogenes and tumor suppressor genes in a genetically homogeneous background present an ideal opportunity to test efficacy of novel miRNA mediated therapeutics [32]. However, knowledge about miRNA expression profiles in the TH-MYCN transgenic mouse model or its variants is lacking, particularly the degree to which murine miRNA expression profiles parallel those of human neuroblastoma. Here, we generated miRNA profiles of murine tumors and adrenal tissues derived from TH-MYCN mice in both wild-type and mutant p53 deficient backgrounds. Our analyses reveal similarities and differences between the miRNA expression profiles of human and mouse neuroblastoma and have allowed us to assess the impact of p53 haploinsufficiency on miRNA expression. By comparing the miRNA profile of murine and human tumors, we demonstrate the extent to which the transgenic mouse model can be used for miRNAs related studies.

Results

miRNA expression profiling of murine tumors

In order to identify miRNAs associated with neuroblastoma tumorigenesis, we analyzed the expression of 391 murine miRNAs in 22 mouse tumors using TaqMan low density arrays. Nine tumors were derived from TH-MYCN mice (wild-type for p53) and 13 from TH-MYCN mice in a p53 deficient background (TH-MYCN/p53ER<sup>TAM</sup> mice). As a control group, we profiled 12 adrenal glands (three from TH-MYCN; five from TH-MYCN/p53ER<sup>TAM</sup>; and four from wild-type mice) coming from young mice (7 days after birth). Adrenals coming from TH-MYCN and wild-type mice were stained with hematoxylin and cosin, confirming that the tissues were histologically normal in the transgenic mice (Figure S1). After primary profiling, the data set was filtered to include 440 miRNAs with expression in at least 10 of the samples (Figure S2).

Unsupervised hierarchical clustering based on the expression of the total dataset of 440 miRNAs (Table S1) resolved tumors from adrenal gland controls (Figure 1A). Before using the adrenals as a unique group of controls regardless their genotype, we analyzed the miRNA expression of TH-MYCN (n = 8) and wild type (n = 4) adrenals finding no statistically significant differences. Then we compared all tumors (n = 22) to all adrenal controls (n = 12). Using the Wilcoxon Rank Sum Test corrected for multiple comparisons (n = 440), we found 159 miRNAs differentially regulated (p < 0.05) in tumors; 81 were over-expressed (>2-fold) and 78 were under-expressed (<2-fold) (Table S2). Thus, miRNA expression in tumor tissue compared to a developmentally differentiated tissue precursor is significantly differentially regulated. Intriguingly, haploinsufficiency for p53 did not dramatically alter miRNA expression patterns as the tumor samples clustered together regardless their genotype.

Since the miRNA profiles did not show any major differences based on the presence of the p53-ER<sup>TAM</sup> allele, we measured expression of the endogenous p53 transcript in tumors to confirm haploinsufficiency. The primers were designed to detect expression of the endogenous wild-type p53 allele, and not the mutant p53-ER<sup>TAM</sup> allele (Figure S3A). Five TH-MYCN and 6 TH-MYCN/p53ER<sup>TAM</sup> tumors were analyzed through quantitative PCR. All TH-MYCN/p53ER<sup>TAM</sup> animals showed a reduced level of wild-type p53 mRNA (t-test, p < 0.0001) (Figure S3B). These data demonstrate that no compensatory up-regulation of the endogenous p53 allele occurs in TH-MYCN/p53ER<sup>TAM</sup> tumors.

Although cluster analysis based on all miRNAs did not distinguish tumors with respect to p53 genotype, miR-125b-3p and miR-676 were significantly down-regulated (p < 0.03) in TH-MYCN/p53ER<sup>TAM</sup> tumors (Figure 1B-C) based on the Wilcoxon Rank Sum Test with p-values corrected for multiple comparisons (n = 440).

Cross-Comparison of miRNA expression in human and murine tumors

In order to assess the relevance of the mouse model as a representative platform for studies of important miRNA targets modulated in human neuroblastoma, we first compared the set of miRNAs differentially expressed in mouse and human tumors, using previously published miRNA expression profiles of human neuroblastoma [12,16]. In total, 296 mature miRNAs are conserved between mouse and human in the miRBase version 16 (Table S3). Taking into account only conserved miRNAs (Figure S4A), a total of 63 miRNAs have been identified as differentially expressed in human MNA versus non-MNA tumors in at least one published study [12,16]. Among the 63 conserved miRNAs differentially expressed between human MNA versus non-MNA tumors, 29 (46%) were differentially expressed between mouse tumors and adrenals (Figure S4B). This amount of overlap between differentially expressed miRNAs in human versus mouse tumors is statistically significant (p < 0.01) according to a hypergeometric distribution [33]. The majority of the miRNAs had alterations in expression that were consistent between the two species, except for miR-323-3p, miR-369-3p, miR-410, miR-411, miR-433, miR-494 and miR-130a, which were expressed discordantly in the tumors from the two different species (Table 1). It is interesting to note that 6 out of 7 of the miRNAs
that were inconsistent in the mouse/human comparison map to a large cluster on chromosome 14q in humans (mouse chromosome 12). Overall, these results showed high concordance in miRNA expression between murine and human neuroblastoma, with the aforementioned exceptions.

Using data previously obtained in our laboratory, we directly compared the miRNA profile of human and mouse tumors. The cohort of 146 human tumors included 36 tumors MNA and 110 samples non-MNA [12]. Comparison between human and mouse tumors was complicated by the fact that not all miRNAs in the
Table 1. miRNAs differentially expressed in mouse and human tumors.

| MiRNA NAME | MOUSE TUMORS | HUMAN MNA TUMORS |
|------------|--------------|------------------|
|            | Bray et al.  | Mestdagh et al.  |
| miR-130b   | Up           | Up               |
| miR-17     | Up           | Up               |
| miR-18a    | Up           | Up               |
| miR-19a    | Up           | Up               |
| miR-19b    | Up           | Up               |
| miR-20a    | Up           | Up               |
| miR-20b    | Up           | Up               |
| miR-25     | Up           | Up               |
| miR-9      | Up           | Up               |
| miR-9*     | Up           | Up               |
| miR-93     | Up           | Up               |
| miR-323-3p | Up           | Down             |
| miR-369-5p | Up           | Down             |
| miR-410    | Up           | Down             |
| miR-411    | Up           | Down             |
| miR-433    | Up           | Down             |
| miR-494    | Up           | Down             |
| miR-152    | Down         | Down             |
| miR-204    | Down         | Down             |
| miR-26a    | Down         | Down             |
| miR-26b    | Down         | Down             |
| miR-30a    | Down         | Down             |
| miR-30a*   | Down         | Down             |
| miR-30d    | Down         | Down             |
| miR-30e    | Down         | Down             |
| miR-30e*   | Down         | Down             |
| miR-328    | Down         | Down             |
| miR-491    | Down         | Down             |
| miR-130a   | Down         | Up               |

Up = Over-expressed in MNA tumors; Down = under-expressed in MNA tumors.
doi:10.1371/journal.pone.0028356.t001

The importance of highly representative murine models for studying human pathologies and for developing new pharmacological treatments is established [32], however it is necessary to determine on a case-by-case basis the degree to which each model faithfully mimics human pathology. The TH-MYCN murine model for neuroblastoma has been well-characterized from the histopathological, gene expression and genome instability point of view [24–26,34]. Here, we identify miRNAs that are differentially expressed in this model (relative to adrenal controls). Cross-comparison between this and previous human studies reveals similarities and differences between the mouse model and the human pathology with regard to miRNA expression. The miRNA profile across murine tumors is more homogeneous than that observed in human tumors, perhaps a reflection of the inbred genetic tumor environment in murine versus human tumors. This
supports the use of mouse models for studying pathological events in a more defined genetic background, with reduced heterogeneity due to genetic variation that often affects human studies.

In total, 22 conserved miRNAs were differentially expressed across both murine tumor versus adrenal and human MNA versus non-MNA tumors (as identified in at least one of two independent studies on human tumors [12,16]). This degree of similarity between human and mouse tumors is consistent with interspecies comparisons for other types of tumors [35]. Notably, several members of the miR-17-92 polycistronic cluster, which are highly up-regulated in human MNA tumors [36], were up-regulated in mouse tumors relative to the adrenal glands. This polycistronic cluster has demonstrated oncogenic functions in neuroblastoma through targeting multiple genes of the TGFβ signaling pathway [18,19]. Similarly, miR-9, which is positively regulated by MYCN in human neuroblastoma [37], was also significantly up-regulated in the mouse tumors. In addition, miR-152 is down-regulated in both mouse and human neuroblastoma, having a documented tumor suppressor function in human neuroblastoma [38]. Overall, our results in the mouse model indicate that the over-expression of MYCN strongly deregulates miRNAs expression, similar to the situation in human neuroblastoma.

The major tumor suppressor miRNA, miR-34a, which is down-regulated in human neuroblastoma, was not changed in the mouse tumors and represents an example of where the mouse model is inconsistent with human neuroblastoma. Many factors are likely to account for the differences in miRNA expression between human and mouse neuroblastoma. For example, in addition to MYCN, large-scale genomic imbalances have been demonstrated to influence miRNA expression in human tumors [12]. Although some similarities in genomic imbalances have been demonstrated between murine and human tumors [34], there are also extensive differences between human and mouse genomes resulting from the accumulation of approximately 200 chromosomal rearrangements since the evolutionary divergence of rodent and primate lineages.

It is also important to realize that neuroblastoma originate from fetal neuroblasts [39], so that some differences in miRNA expression between tumors and adrenal glands (from 7 day old mice) could relate to differentiation associated changes rather than cancer specific alterations. This possibility requires further testing by profiling micro-dissected fetal neuroblasts, a technically challenging endeavor.

P53 is a critical tumor suppressor gene inactivated in a variety of cancers. In neuroblastoma, p53 is rarely inactivated in...
primary tumors, but is often mutated in recurrent tumors. Although the p53 transcription factor is known to regulate a number of miRNAs, including miR-34a, miR-23b, miR-26, miR-30, miR-107 and miR-192 [40–45], there was very little difference in miRNA expression patterns between tumors derived from p53 wild-type TH-MYCN versus p53 mutant TH-MYCN mice, despite significant differences in tumor phenotype when MYCN drives neuroblastoma in a p53 deficient background [25]. This implies that p53 mediated regulation of miRNAs requires complete abrogation of p53 activity rather than p53 haploinsufficiency. Certainly this was the case for p53 regulation of miR-34a, where the effects of p53

Figure 3. Analysis of human and mouse samples based on miRNAs (n = 43) deregulated in human MNA. (A) Hierarchical clustering (n = 43). Cluster “Mouse” contains all the mouse samples, split in two branches “Tumors” and controls “Adrenals”. Cluster “Human” includes all the human samples split in two branches which shows an enrichment (p<0.05) for MNA tumors (59.5%, in cluster “MNA”) and an under-representation of MNA samples (12.9%, in cluster “non-MNA”), respectively. (B) Principal component analysis. Line “a” splits the samples based on the species: human (left) and mouse (right). Line “b” shows a distribution of the samples according to MYCN expression: a clear split in the mouse and an enrichment (p<0.001) for human MNA samples (under). Mouse tumors (green), mouse adrenals (black), human MNA (red) and human non-MNA (purple). doi:10.1371/journal.pone.0028356.g003
were investigated in a p53-homozygous mouse knockout model [44,46]. Thus, we hypothesize that the modulation of miRNAs induced by p53 is not dose dependent in our model and that the vast majority of miRNAs are not significantly involved in the more aggressive phenotype driven by p53 haploinsufficiency. However, confirmation of this supposition would require the analysis of miRNA expression derived from mice homozygous for mutant p53.

Figure 4. Analysis of human and mouse samples based on miRNAs (n = 63) deregulated in mice tumors. A. Hierarchical clustering. Cluster "Adrenals" contains all the mouse adrenals. Cluster "Tumors" collects all the "Mouse" and "Human" tumors, highlighting a branch enriched (p<0.01) for human non-MNA samples (90.7%). B. Principal component analysis. Line "a" splits the samples based on the species: mouse (under) and human (above). Line "b" separates the samples according to the presence of the pathology: controls (left) and tumors (right). Mouse tumors (green), mouse adrenals (black), human MNA (red) and human non-MNA (purple). doi:10.1371/journal.pone.0028356.g004
The only two miRNAs that were down-regulated in TH-MYCN tumors from TH-MYCN/p53ER\(^{Tam}\) mice were miR-125b-3p and miR-676. No specific role has thus far been ascribed to miR-676 in human neuroblastoma, which has a seed region that is not identical between the two species. Interestingly, miR-125b has been identified as both a target of p53 [47] and a regulator of the p53 transcript itself [48]. miR-125b inhibits neuroblastoma cell proliferation and promotes cell differentiation in vitro [49,50], so that down-regulation of this miRNA could potentially be contributing towards the more aggressive phenotype of the TH-MYCN/p53-ER\(^{Tam}\) tumor phenotype. This is an interesting possibility requiring further studies.

Although many of the differentially expressed miRNAs were previously identified as being associated with human neuroblastoma (Table 1), this study identifies additional miRNAs not previously correlated with this pathology, indicating a potential role in neuroblastoma pathogenesis. Indeed, many of the most significantly differentiated miRNAs in mouse tumors versus adrenal tissue have never been associated with any form of cancer to date (Table S2). Functional studies are required to corroborate any role that these miRNAs might have in tumorigenesis. Lastly we demonstrate that, despite some differences among the two species, the mouse model recapitulates a pattern of miRNA expression that is dependent on MYCN expression and which is similar to the one observed in human MNA tumors. Our results further support the involvement of miRNAs in neuroblastoma, validating the utility of TH-MYCN mouse model for studying the role of miRNAs in this pathology and for possible pre-clinical trials based on miRNA agonist/antagonist molecules.

**Materials and Methods**

Transgenic mice and samples collection

TH-MYCN mice were maintained in hemizygotic matings [26]. TH-MYCN/p53ER\(^{Tam}\) animals were obtained serially crossing TH-MYCN+/- and p53-ER +/- mice [25]. Adrenals were obtained from mice 7 day post birth, while tumors were collected after the onset of the tumor pathology (>40 days post birth). All tissue samples were either frozen in liquid nitrogen or submerged in RINaLater RNA Stabilization Reagent (Qiagen, Crawley, UK) and stored at -80°C. All animals were handled in accordance with institutional guidelines for safe and ethical treatment of mice. The protocol was approved by the U.K. Home Office (License number PPL70/6892).

RNA isolation

Total RNA extraction was performed using RNeasy (Qiagen), miRNeasy (Qiagen), or mirVana\(^{TM}\) miRNA Isolation Kit (Ambion, Austin, Texas) following the manufacturer guidelines.

Reverse transcription

For messenger RNA (mRNA) cDNA synthesis, total RNA was reverse transcribed using random primers and a TaqMan Reverse Transcription kit (Applied Byosistems, Foster City, CA). Up to 762 rodent mature miRNAs were converted to cDNA (381 miRNAs processed simultaneously per reaction) using the Megaplex\(^{TM}\) RT Rodent Pool (Applied Biosystems).

Quantitative PCR for gene expression

The level of endogenous p53 was analyzed using primers specifically designed for targeting exon 10 and 11 of the transcript (sequences of primers available on request) and SYBR\(^{\circledR}\) Green PCR Master Mix (Applied Biosystem); mRNA quantifications were normalized to the housekeeping gene β-actin. Relative quantification of genes expression was determined using the comparative cycle threshold method (2\(^{-\Delta\Delta CT}\)).

Pre-amplification and quantitative PCR of miRNAs

Megaplex retro transcription product was pre-amplified using TaqMan PreAmp Master Mix and Megaplex\(^{TM}\) PreAmp Primers, Rodent Pool (Applied Biosystems). The miRNA profile of each cDNA sample was obtained using 384-well microfluidic cards (TaqMan\(^{\circledR}\) MicroRNA Array v2.0, Applied Biosystems). As instrument and liquid handling variations were shown to be minimal, no PCR replicates were measured. All quantitative PCR (qPCR) were carried out on the 7900 HT Fast Real-time System (Applied Biosystems).

Data analysis

Since the presence of a single molecule of target lead to a Ct value of 35, all miRNAs with Ct values greater than 35 were considered not expressed. The mean Ct of a sample was subtracted from the Ct value of each miRNA among that sample (mean centered normalization) before calculating relative expression values [51]. Normalized relative expression (NRQ) of miRNA was calculated with reference to the Cmax (maximum Ct value for an individual miRNA across all samples) using: NRQ = 2(Cmax–Ct).

Significance testing

The statistical significance of miRNA differential expression over sample classes was evaluated by assigning p-values based on the non-parametric Wilcoxon Rank Sum Test. P-values were corrected for multiple comparisons using the Bonferroni method. The statistical significance of the enrichment for a specific genotype among the groups generated by the hierarchical clustering was evaluated using the chi-squared test (x2-test) on the frequency of observed samples compared to the expected random distribution. The statistical significance of the overlap between the lists of miRNAs was evaluated using the hypergeometric distribution [33].

miRNA homology identification

An in-house developed Java (v6.0) software was used for comparing the sequences (retrieved from miRBase v16) of human and mouse mature miRNAs. We considered as homologue only miRNAs whose mature transcript showed perfect identity in both length and nucleotide sequence among the two species.

Cluster analysis and visualization

Hierarchical clustering, heatmap generation, principal component analysis (PCA) and the loadings of PCA were performed using “hcclust” (agglomeration method complete based on Spearman rank correlation coefficient), “heatmap.2”, “pcomp” and “pcs$rotation” functions of the R statistical computing language v2.13.0.

Supporting Information

Figure S1 Comparison of hematoxylin and eosin stained adrenal glands from wild-type and transgenic mice at day 7 after birth. The gross size is similar in transgenic versus wild-type mice and there is no evidence of changes in cell morphology indicative of hyperplasia or the development of early proliferative intra-adrenal preneoplastic foci. (TIF)
Figure S2 Overview of the data flow and analyses. Schematic representation of the concept of the project and of the steps in the analysis.
(TIF)

Figure S3 Analyses of p53 endogenous expression in wild type and deficient p53 tumors. A. Schematic representation of the primer design for the specific detection of the endogenous p53 transcript. B. Expression of endogenous p53 transcript in TH-MYCN and TH-MYCN/p53ER<sup>TAM</sup> tumors. The samples from p53 wild type mice (n = 5) express approximately 2-fold more endogenous p53 (p<0.001) compared to TH-MYCN/p33ER<sup>TAM</sup> tumors (n = 6).
(TIF)

Figure S4 Comparison between miRNAs differentially expressed in human and mouse neuroblastoma tumors. A. Schematic representation of the clearing process for comparing the lists becoming from studies on different species. B. Venn diagram representing the overlapping of miRNAs deregulated in human and mice neuroblastoma. miRNAs differentially expressed in mouse tumors compared to adrenals (pink circle), miRNAs deregulated in human MNA compared to non-MNA in Bray human and mice neuroblastoma. miRNAs differentially expressed in human MNA compared to non-MNA Mestdagh (green circle).
(TIF)

References

1. Stallings RL (2007) Are chromosomal imbalances important in cancer? Trends Genet 23: 278–283.
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124.
3. Murphy DM, Buckley PG, Bryan K, Das S, Akkoc L, et al. (2009) Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4: e1154.
4. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Cancer 10: 403–411.
5. Westerman F, Muth D, Benner A, Bauer T, Heinrich KO, et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
6. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522–531.
7. He X, He L, Hannon GJ (2007) The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67: 11099–11101.
8. Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43: 1529–1544.
9. Stallings RL (2009) MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapies. Curr Pharm Des 15: 456–462.
10. Stallings RL, Foley NH, Bray IM, Das S, Buckley PG (2011) MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. Semin Cancer Biol 21: 283–290.
11. Stallings RL, Foley NH, Bryan K, Buckley PG, Bray I (2010) Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 14: 951–962.
12. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, et al. (2009) Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4: e7150.
13. Buckley PG, Akkoc L, Bryan K, Bray I, Schulte JH, et al. (2010) Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q15 neuroblastoma. Clin Cancer Res 16: 2971–2978.
14. Chen Y, Stallings RL (2007) Differential patterns of microRNA expression in neuroblastomas are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976–983.
15. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, et al. (2010) microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 70: 7941–7950.
16. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, et al. (2010) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29: 1394–1404.
17. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, et al. (2010) Accurate prediction of neuroblastoma outcome based on microRNA expression profiles. Int J Cancer 127: 2374–2383.
18. Fontana L, Fusi ME, Albini S, Cifaldi L, Giovannazzi N, et al. (2008) Antagonism of miR-15-19p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236.
19. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, et al. (2011) The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 49: 762–773.
20. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9: 83.
21. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017–5022.
22. Foley NH, Bray I, Watters KM, Das S, Bryan K, et al. (2011) MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 18: 1089–1096.
23. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, et al. (2011) MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303: 56–64.
24. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985–2995.
25. Chesler E, Goldenberg DD, Collins R, Grimmer M, Kim GE, et al. (2008) Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10: 1260–1274.
26. Chesler E, Goldenberg DD, Koochesfahani M, Grimmer M, et al. (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67: 9435–9442.
27. Christopoulos MA, Martin-Zanca D, Sousek L, Lavlov ER, Brown-Swiggart L, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718–726.
28. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, et al. (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5: 2639–2647.
29. Carr J, Bell E, Pearson AD, Kees UR, Beris H, et al. (2006) Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 66: 2138–2145.
30. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377–1388.
31. Slack A, Lozano G, Shohet J M (2005) MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 228: 21–27.
32. Teixe T, Stanke JJ, Federico S, Bradley CL, Brennan R, et al. (2011) Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 6: e19133.
33. Fury W, Batliwalla F, Gregersen PK, Li W (2006) Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion. Conf Proc IEEE Eng Med Biol Soc 1: 5531–5534.
34. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, et al. (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63: 5266–5273.
35. Zhu M, Yi M, Kim CH, Deng C, Li Y, et al. (2011) Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol 12: R77.
36. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, et al. (2008) MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122: 699–704.
37. Ma L, Young J, Prabhala H, Pan F, Mestdagh P, et al. (2010) miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247–256.
38. Das S, Foley N, Bryan K, Watters KM, Bray I, et al. (2010) MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res 70: 7874–7881.
39. De Preter K, Vandewempele J, Heinemann P, Yigit N, Beckman S, et al. (2006) Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Res 7: R84.
40. Bohlig L, Friedrich M, Engelund K (2011) p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 39: 440–453.
41. Boominathan L (2011) The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor microRNAs network. Cancer Metastasis Rev 29: 613–639.
42. Pichiorri F, Suh SS, Rocca A, De Luca L, Taccioli C, et al. (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18: 367–381.
43. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 743–752.
44. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731–743.
45. Tarasov V, Jung P, Verdoold B, Ledheyin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1386–1393.
46. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130–1134.
47. Gueta K, Molotski N, Gerchikov N, Mor E, Savion S, et al. (2010) Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype. BMC Dev Biol 10: 20.
48. Le MT, Teh C, Sbyh-Chiang N, Xie H, Zhou B, et al. (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23: 862–876.
49. Lanwepe P, Di Marcotullio I, Gisela U, Fiori ME, Ferretti E, et al. (2007) The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A 104: 7957–7962.
50. Le MT, Xie H, Zhou B, Chia PH, Rick P, et al. (2009) MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 29: 5390–5395.
51. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, et al. (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.